Vice President, Translational Informatics
As Vice President, Translational Informatics at Roivant Discovery, Tudor leads translational informatics efforts ranging from targets through drug discovery as we advance our pipeline of medicines to the clinic. Tudor joined Roivant Discovery from the University of New Mexico. Tudor is a digital drug hunter with three decades of experience in machine learning and knowledge management applied to target and drug discovery.
At the University of New Mexico, Tudor served as director for screening informatics and, ultimately as chief of translational informatics where he received over $24 million in extramural funding for a broad range of projects. Prior to the University of New Mexico, Tudor worked at AstraZeneca where he conceptually developed the “lead-like approach” for combinatorial chemistry and fragment-based drug discovery. Tudor co-invented the first G-protein coupled estrogen receptor agonist, an orphan drug designated compound for uveal melanoma. He has developed machine learning models since 1989, first in cheminformatics and quantitative structure-activity relationship (QSAR) and later in disease and target biology. Tudor has co-authored over 270 publications, edited two books on informatics in drug discovery, has been awarded 10 U.S. patents and has been cited nearly 23,000 times.
Tudor received his M.D. in general medicine (1990) and Ph.D. in molecular physiology (1992) from the University of Medicine and Pharmacy in Timişoara, Romania.